AU · rank #4 · 2026-09-04
NUTX
NASDAQ · $1.31B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.738 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$5.80 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.171 |
| Analyst upside Consensus target $276.00 | +39.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +16.55% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +54.5% |
| 52w high | $204.00 |
| Market cap (USD) | $1.31B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health operates a physician-led integrated healthcare delivery system consisting of 27 micro-hospitals and outpatient departments alongside risk-bearing primary care physician networks.
Rationale
A massive 89.3% Q2 earnings surprise and strong shift to H1 2026 profitability validate the quant model's signal of 100% positive analyst EPS revisions and a 39.6% target upside.
Material risks
- 1Negative reimbursement impacts stemming from heightened No Surprises Act scrutiny and the Fifth Circuit's rejection of "ghost rates" in federal QPA calculations.
- 2Potential margin contraction if the recent reductions in contract services expenses and stock-based compensation prove unsustainable.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.